Stephan Vagner

List of Publications by Year
in descending order

62	5,519	101543	128289
papers	citations	36 h-index	60 g-index

68	68	68	9196
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma. Clinical Cancer Research, 2022, 28, 518-525.	7.0	7
2	Differential Effects on the Translation of Immune-Related Alternatively Polyadenylated mRNAs in Melanoma and T Cells by eIF4A Inhibition. Cancers, 2022, 14, 1177.	3.7	5
3	Glycolysis Dependency as a Hallmark of SF3B1-Mutated Cells. Cancers, 2022, 14, 2113.	3.7	3
4	At the crossroads of RNA biology, genome integrity and cancer. Bulletin Du Cancer, 2022, , .	1.6	0
5	Reciprocal Links between Pre-messenger RNA 3â€²-End Processing and Genome Stability. Trends in Biochemical Sciences, 2021, 46, 579-594.	7.5	8
6	The plasticity of mRNA translation during cancer progression and therapy resistance. Nature Reviews Cancer, 2021, 21, 558-577.	28.4	100
7	In situ detection of the eIF4F translation initiation complex in mammalian cells and tissues. STAR Protocols, 2021, 2, 100621.	1.2	1
8	Flavaglines as natural products targeting eIF4A and prohibitins: From traditional Chinese medicine to antiviral activity against coronaviruses. European Journal of Medicinal Chemistry, 2020, 203, 112653.	5.5	31
9	Persistent Cancer Cells: The Deadly Survivors. Cell, 2020, 183, 860-874.	28.9	157
10	ZRANB2 and SYF2-mediated splicing programs converging on ECT2 are involved in breast cancer cell resistance to doxorubicin. Nucleic Acids Research, 2020, 48, 2676-2693.	14.5	30
11	An epitranscriptomic mechanism underlies selective mRNA translation remodelling in melanoma persister cells. Nature Communications, 2019, 10, 5713.	12.8	70
12	Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer. Clinical Cancer Research, 2019, 25, 710-723.	7.0	12
13	Translational control of tumor immune escape via the eIF4Fâ€“STAT1â€“PD-L1 axis in melanoma. Nature Medicine, 2018, 24, 1877-1886.	30.7	180
14	Boosting Immunity by Targeting Post-translational Prenylation of Small GTPases. Cell, 2018, 175, 901-902.	28.9	5
15	Regulation of RNA polymerase III transcription during transformation of human IMR90 fibroblasts with defined genetic elements. Cell Cycle, 2018, 17, 605-615.	2.6	21
16	Discovery of Iminobenzimidazole Derivatives as Novel Cytotoxic Agents. Open Medicinal Chemistry Journal, 2018, 12, 74-83.	2.4	0
17	The G-Quadruplex-Specific RNA Helicase DHX36 Regulates p53 Pre-mRNA 3â€²-End Processing Following UV-Induced DNA Damage. Journal of Molecular Biology, 2017, 429, 3121-3131.	4.2	46
18	Molecular Pathways: The eIF4F Translation Initiation Complexâ€"New Opportunities for Cancer Treatment. Clinical Cancer Research, 2017, 23, 21-25.	7.0	75

#	Article	IF	Citations
19	DNA-Damage Response RNA-Binding Proteins (DDRBPs): Perspectives from a New Class of Proteins and Their RNA Targets. Journal of Molecular Biology, 2017, 429, 3139-3145.	4.2	36
20	Synergistic effects of eIF4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell lines. Cell Cycle, 2016, 15, 2405-2409.	2.6	11
21	Translational regulation of the mRNA encoding the ubiquitin peptidase USP1 involved in the DNA damage response as a determinant of Cisplatin resistance. Cell Cycle, 2016, 15, 295-302.	2.6	23
22	Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAFâ€“CRAF Heterodimerization. Cancer Research, 2016, 76, 1476-1484.	0.9	44
23	hnRNP A1-mediated translational regulation of the G quadruplex-containing RON receptor tyrosine kinase mRNA linked to tumor progression. Oncotarget, 2016, 7, 16793-16805.	1.8	30
24	Vemurafenib Cooperates with HPV to Promote Initiation of Cutaneous Tumors. Cancer Research, 2014, 74, 2238-2245.	0.9	28
25	Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature, 2014, 508, 118-122.	27.8	702
26	DNA damage: RNA-binding proteins protect from near and far. Trends in Biochemical Sciences, 2014, 39, 141-149.	7.5	103
27	Dramatic response to radiotherapy combined with vemurafenib. Is vemurafenib a radiosensitizer?. European Journal of Dermatology, 2014, 24, 265-267.	0.6	10
28	eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. Nature, 2014, 513, 105-109.	27.8	287
29	Age at cancer onset in germline TP53 mutation carriers: association with polymorphisms in predicted G-quadruplex structures. Carcinogenesis, 2014, 35, 807-815.	2.8	29
30	Genome-Wide Analysis of Host mRNA Translation during Hepatitis C Virus Infection. Journal of Virology, 2013, 87, 6668-6677.	3.4	21
31	Targeting the Deregulated Spliceosome Core Machinery in Cancer Cells Triggers mTOR Blockade and Autophagy. Cancer Research, 2013, 73, 2247-2258.	0.9	86
32	Skin Tumors Induced by Sorafenib; Paradoxic RASâ€“RAF Pathway Activation and Oncogenic Mutations of HRAS, TP53, and TGFBR1. Clinical Cancer Research, 2012, 18, 263-272.	7.0	119
33	Decreased efficiency of MSH6 mRNA polyadenylation linked to a 20-base-pair duplication in Lynch syndrome families. Cell Cycle, 2012, 11, 2578-2580.	2.6	8
34	Splicing switch of an epigenetic regulator by RNA helicases promotes tumor-cell invasiveness. Nature Structural and Molecular Biology, 2012, 19, 1139-1146.	8.2	117
35	Gâ€quadruplexes in RNA biology. Wiley Interdisciplinary Reviews RNA, 2012, 3, 495-507.	6.4	247
36	Formation of the eIF4F Translationâ€“Initiation Complex Determines Sensitivity to Anticancer Drugs Targeting the EGFR and HER2 Receptors. Cancer Research, 2011, 71, 4068-4073.	0.9	49

#	Article	IF	Citations
37	Essential role for the interaction between hnRNP H/F and a G quadruplex in maintaining p53 pre-mRNA 3â€²-end processing and function during DNA damage. Genes and Development, 2011, 25, 220-225.	5.9	155
38	Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC. Clinical Cancer Research, 2011, 17, 5562-5572.	7.0	56
39	The c.5242C>A BRCA1 missense variant induces exon skipping by increasing splicing repressors binding. Breast Cancer Research and Treatment, 2010, 120, 391-399.	2.5	23
40	Nucleotide Variability and Translation Efficiency of the 5â€² Untranslated Region of Hepatitis A Virus: Update from Clinical Isolates Associated with Mild and Severe Hepatitis. Journal of Virology, 2010, 84, 10139-10147.	3.4	18
41	Molecular mechanisms of eukaryotic pre-mRNA 3â€² end processing regulation. Nucleic Acids Research, 2010, 38, 2757-2774.	14.5	322
42	Exon-Based Clustering of Murine Breast Tumor Transcriptomes Reveals Alternative Exons Whose Expression Is Associated with Metastasis. Cancer Research, 2010, 70, 896-905.	0.9	59
43	Occult infection of peripheral B cells by hepatitis C variants which have low translational efficiency in cultured hepatocytes. Gut, 2010, 59, 934-942.	12.1	42
44	Alternative splicing and breast cancer. RNA Biology, 2010, 7, 403-411.	3.1	35
45	Widespread Estrogen-Dependent Repression of microRNAs Involved in Breast Tumor Cell Growth. Cancer Research, 2009, 69, 8332-8340.	0.9	225
46	A physical and functional link between splicing factors promotes pre-mRNA 3â€² end processing. Nucleic Acids Research, 2009, 37, 4672-4683.	14.5	68
47	Post-transcriptional control of gene expression through subcellular relocalization of mRNA binding proteins. Biochemical Pharmacology, 2008, 76, 1395-1403.	4.4	21
48	Characterization of a Short Isoform of Human Tgs1 Hypermethylase Associating with Small Nucleolar Ribonucleoprotein Core Proteins and Produced by Limited Proteolytic Processing. Journal of Biological Chemistry, 2008, 283, 2060-2069.	3.4	39
49	Subcellular Relocalization of a Trans-acting Factor Regulates XIAP IRES-dependent Translation. Molecular Biology of the Cell, 2007, 18, 1302-1311.	2.1	99
50	Cytoplasmic Relocalization of Heterogeneous Nuclear Ribonucleoprotein A1 Controls Translation Initiation of Specific mRNAs. Molecular Biology of the Cell, 2007, 18, 5048-5059.	2.1	128
51	An interaction between U2AF 65 and CF Im links the splicing and 3â€² end processing machineries. EMBO Journal, 2006, 25, 4854-4864.	7.8	179
52	Testosterone regulates FGFâ€2 expression during testis maturation by an IRESâ€dependent translational mechanism. FASEB Journal, 2006, 20, 476-478.	0.5	49
53	Heterogeneous Nuclear Ribonucleoprotein A1 Is a Novel Internal Ribosome Entry Site trans-Acting Factor That Modulates Alternative Initiation of Translation of the Fibroblast Growth Factor 2 mRNA. Journal of Biological Chemistry, 2005, 280, 4144-4153.	3.4	134
54	Pharmacologicalâ€based translational induction of transgene expression in mammalian cells. EMBO Reports, 2004, 5, 721-727.	4.5	15

#	Article	IF	Citations
55	Generation of protein isoform diversity by alternative initiation of translation at non-AUG codons. Biology of the Cell, 2003, 95, 169-178.	2.0	220
56	A Single Internal Ribosome Entry Site Containing a G Quartet RNA Structure Drives Fibroblast Growth Factor 2 Gene Expression at Four Alternative Translation Initiation Codons. Journal of Biological Chemistry, 2003, 278, 39330-39336.	3.4	151
57	IRESdb: the Internal Ribosome Entry Site database. Nucleic Acids Research, 2003, 31, 427-428.	14.5	79
58	A novel function for the U2AF 65 splicing factor in promoting preâ€mRNA 3â€²â€end processing. EMBO Reports, 2002, 3, 869-874.	4.5	57
59	Irresistible IRES. EMBO Reports, 2001, 2, 893-898.	4.5	247
60	Position-dependent inhibition of the cleavage step of pre-mRNA 3â€²-end processing by U1 snRNP. Rna, 2000, 6, 178-188.	3.5	69
61	Alternative Translation of the Proto-oncogene c-mycby an Internal Ribosome Entry Site. Journal of Biological Chemistry, 1997, 272, 32061-32066.	3.4	219
62	Alternative Translation Initiation of the Moloney Murine Leukemia Virus mRNA Controlled by Internal Ribosome Entry Involving the p57/PTB Splicing Factor. Journal of Biological Chemistry, 1995, 270, 20376-20383.	3.4	108